DE69309492T2 - Antipyretische und analgetische zusammensetzungen, die optisch reines r-ketorolac enthalten - Google Patents

Antipyretische und analgetische zusammensetzungen, die optisch reines r-ketorolac enthalten

Info

Publication number
DE69309492T2
DE69309492T2 DE69309492T DE69309492T DE69309492T2 DE 69309492 T2 DE69309492 T2 DE 69309492T2 DE 69309492 T DE69309492 T DE 69309492T DE 69309492 T DE69309492 T DE 69309492T DE 69309492 T2 DE69309492 T2 DE 69309492T2
Authority
DE
Germany
Prior art keywords
ketorolac
pain
optically pure
antipyretic
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69309492T
Other languages
English (en)
Other versions
DE69309492D1 (de
Inventor
Timothy J Barberich
Stephen L Matson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of DE69309492D1 publication Critical patent/DE69309492D1/de
Publication of DE69309492T2 publication Critical patent/DE69309492T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69309492T 1992-12-17 1993-12-17 Antipyretische und analgetische zusammensetzungen, die optisch reines r-ketorolac enthalten Expired - Fee Related DE69309492T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99198192A 1992-12-17 1992-12-17
PCT/US1993/012299 WO1994013283A1 (en) 1992-12-17 1993-12-17 Antipyretic and analgesic methods and compositions containing optically pure r-ketorolac

Publications (2)

Publication Number Publication Date
DE69309492D1 DE69309492D1 (de) 1997-05-07
DE69309492T2 true DE69309492T2 (de) 1997-07-10

Family

ID=25537797

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69309492T Expired - Fee Related DE69309492T2 (de) 1992-12-17 1993-12-17 Antipyretische und analgetische zusammensetzungen, die optisch reines r-ketorolac enthalten

Country Status (14)

Country Link
US (1) US5382591A (de)
EP (1) EP0674511B1 (de)
JP (1) JP2957701B2 (de)
KR (1) KR100264814B1 (de)
AT (1) ATE150969T1 (de)
AU (1) AU696620B2 (de)
CA (1) CA2151724C (de)
DE (1) DE69309492T2 (de)
DK (1) DK0674511T3 (de)
ES (1) ES2100046T3 (de)
FI (1) FI952985A (de)
GR (1) GR3023741T3 (de)
NO (1) NO307546B1 (de)
WO (1) WO1994013283A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464609A (en) * 1990-03-16 1995-11-07 The Procter & Gamble Company Use of ketorolac for treatment of oral diseases and conditions
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
EP1642575B1 (de) * 1997-03-10 2009-10-28 Loma Linda University Medical Center Verwendung von r-carprofen zur Vorbeugung der Alzheimerschen Krankheit
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6576191B1 (en) * 1999-09-30 2003-06-10 Therox, Inc. Apparatus for blood oxygenation
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
WO2003068159A2 (en) * 2002-02-11 2003-08-21 Wake Forest University Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
EP1603548A4 (de) * 2003-02-05 2007-10-10 Myriad Genetics Inc Verfahren und zusammensetzung zur behandlung neurodegenerativer erkrankungen
CA2532207A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
WO2005014046A2 (en) 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using the same
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
AU2005241023A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US20070042034A1 (en) * 2005-07-22 2007-02-22 Myriad Genetics, Incorporated High drug load formulations and dosage forms
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
MX2008003230A (es) * 2008-03-07 2009-09-07 Senosiain S A De C V Lab Composicion famaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b.
CN112094271B (zh) * 2019-06-18 2023-03-21 鲁南制药集团股份有限公司 一种酮咯酸晶型及其制备方法
CN110540542A (zh) * 2019-09-12 2019-12-06 南京海融制药有限公司 一种苯乙酸类化合物的钠盐、结晶形式及其制备方法
EP4110329A4 (de) * 2020-02-24 2024-04-10 Yinuoke Medicine Science Tech Company Ltd Zusammensetzungen und verfahren zur behandlung von zytokinsturm- und zytokinfreisetzungssyndrom
CN114276350B (zh) * 2020-09-28 2023-05-16 鲁南制药集团股份有限公司 一种酮咯酸与吩嗪共晶及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089969A (en) * 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
JPH01500004A (ja) * 1986-04-16 1989-01-12 ウイスコンシン アラムナイ リサーチ フォンデーション 光学活性1,2―ジヒドロ―3H―ピロロ[1,2a]ピロール―1―カルボン酸誘導体の調製方法
DE69119588T2 (de) * 1990-03-16 1996-11-21 Procter & Gamble Verwendung von ketorolac zur behandlung von periodontitis
JP3541849B2 (ja) * 1991-04-19 2004-07-14 久光製薬株式会社 消炎鎮痛貼付剤
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac

Also Published As

Publication number Publication date
EP0674511B1 (de) 1997-04-02
US5382591A (en) 1995-01-17
AU5872194A (en) 1994-07-04
JP2957701B2 (ja) 1999-10-06
KR100264814B1 (ko) 2000-09-01
EP0674511A1 (de) 1995-10-04
WO1994013283A1 (en) 1994-06-23
AU696620B2 (en) 1998-09-17
NO952418L (no) 1995-08-03
NO952418D0 (no) 1995-06-16
FI952985A (fi) 1995-08-16
CA2151724C (en) 2000-10-31
NO307546B1 (no) 2000-04-25
ATE150969T1 (de) 1997-04-15
DK0674511T3 (da) 1997-04-21
DE69309492D1 (de) 1997-05-07
FI952985A0 (fi) 1995-06-16
ES2100046T3 (es) 1997-06-01
GR3023741T3 (en) 1997-09-30
KR950703951A (ko) 1995-11-17
CA2151724A1 (en) 1994-06-23
JPH08505133A (ja) 1996-06-04

Similar Documents

Publication Publication Date Title
DE69309492T2 (de) Antipyretische und analgetische zusammensetzungen, die optisch reines r-ketorolac enthalten
DE69328838T2 (de) Antipyretische und analgetische verfahren und zusammensetzungen, die optisch reines r-etodolac enthalten
RU94042899A (ru) Способ достижения болеутоляющего эффекта, способ лечения и профилактики гипертермии у человека, болеутоляющая и жаропонижающая композиции, содержащие оптически чистый r (-) кетопрофен
DZ1794A1 (fr) Nouvelle formule pharmaceutique.
DE68919358T2 (de) Zusammensetzung zur behandlung der schizophrenie.
GEP20063720B (en) Triamide-Substituted Indoles, Benzofuranes and Benzothiophenes as Inhibitors of Microsomal Triglyceride Transfer Protein (MTP) and/or Apolipoprotein B (Apo B) Secretion
HUP0203325A2 (hu) Biciklusos aminosavak, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ES2077199T3 (es) Nuevas piperacinas 1,4-disustituidas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
HUP9904360A2 (hu) Eljárás emesis és központi idegrendszeri rendellenességek kezelésére, optikailag tiszta (+)-norciszaprid alkalmazásával
ATE189601T1 (de) Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung viraler erkrankungen
DK0652000T3 (da) Anvendelse af 2-phenyl-3-aroylbenzothiophener til fremstilling af et lægemiddel til inhibering af angiogenese og angiogene sygdomme
ES555118A0 (es) Metodo de preparar medicamentos que incluyen un agente buscador de hueso y un inhibidor de anhidrasa carbonica, para impedir y curar enfermedades oseas.
HUP0000873A2 (hu) A levobupivakain arcsebészeti alkalmazása
NO172640C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive piperazinderivater
DK0769945T3 (da) Brug af 2-phenyl-3-aroylbenzothiophenderivater til fremstilling af et medikament til behandling af knogler og knoglebrud
RU94044487A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия
IT1246050B (it) Impiego dell'eptastigmina nella terapia dell'ictus cerebrale.
NO930083L (no) Sammensetning for behandling av alzheimers sykdom og fremgangsmaate for fremstilling av samme
GEP20002141B (en) Use of 2-Phenyl-1, 2-Benzisoselenazol-3(2H)-One for Prevention and/or Treatment of Dementia, a Pharmaceutical Composition for Prevention and/or Treatment of the Alzheimer’s Disease

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee